The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | The importance of risk-adapted therapies in Hodgkin lymphoma
Sven Borchmann, MD, University of Cologne, Cologne, Germany, discusses the importance of risk-adapted therapies in Hodgkin lymphoma (HL), highlighting the differences between HL and other lymphomas in terms of patient population and outcomes. Dr Borchmann stresses the importance of stratifying patients well to allow de-escalation of treatments where possible, reducing the risk of secondary consequences of treatment. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
